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Abstract
Serum Cu levels rise with age and high Cu/Zn ratios are linked with multiple-cause mortality in
the elderly. The relationships of these parameters to measures of musculoskeletal health and frailty
have not yet been analyzed. We used inductively coupled mass spectrometry to assess serum
levels of Cu and Zn and probed for relationships between serum Cu levels and the Cu/Zn ratio
with specific measures of bone, physical and overall health in a cohort of 144 frail elderly men.
Subjects were divided into quintiles based on serum metal levels and comparisons for functional
measures were made between the reference (middle) group and the low and high groups. Subjects’
serum metal values were normally distributed. We found significant correlations between high Cu/
Zn ratios and deficits in femoral bone mineral density, measures of speed and strength, muscle
mass and hematocrit. High Cu/Zn ratios were also correlated with decreased triglycerides and
increased reliance on ADL assistance. This study identifies specific deficits associated with high
Cu/Zn ratios that span multiple organ systems and supports earlier studies indicating that serum
Cu levels and the Cu/Zn ratio may serve as useful predictive biomarkers for poor health in the
elderly.
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1. Introduction
Cu is essential to life; its redox activity contributes to its utility as a co-factor for electron
transfer reactions. Cuproenzymes like cytochrome c oxidase, Cu/Zn-dependent superoxide
dismutase, lysyl oxidase, tyrosinase, dopamine β-hydroxylase and peptidylglycine α-
amidating monooxygenase are essential to the maintenance of multiple organ systems (Uriu-
Adams et al. 2005). Many other proteins bind Cu and play a role in Cu transport and
homeostasis. Cu deficiency affects the cardiovascular, musculoskeletal, hematopoietic and
nervous systems (Uauy et al. 1998; Uriu-Adams et al. 2005). It is now clear that a complex
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regulatory system governs Cu homeostasis to keep availability of Cu at optimal levels (Kim
et al. 2010).
Cu overload, which can result in oxidative stress and the generation of free-radicals that
contribute to chronic/degenerative diseases and carcinogenesis, is also detrimental (Uriu-
Adams et al. 2005). High serum Cu concentrations have been linked to advancement of
chronic diseases such as diabetes mellitus and Alzheimer’s disease (Uriu-Adams et al. 2005;
Mezzetti et al. 1998; Arnal et al. 2010; Viktorinova et al. 2009). Previous studies linked high
serum Cu and concomitant low serum Zn, another essential element, to mortality in elderly
populations (Leone et al. 2006; Malavolta et al. 2010; Reunanen et al. 1996). Zn competes
with Cu for uptake in the gut and is thought to serve as a natural antioxidant (Uriu-Adams et
al. 2005; Malavolta et al. 2010). In several cases, the Cu/Zn ratio proved to be a better
predictor of disease severity and/or mortality than Cu levels (Leone et al. 2006; Malavolta et
al. 2010; Reunanen et al. 1996; Mezzetti et al. 1998).
Frailty is a geriatric syndrome characterized by low functional and physiologic reserve
resulting in increased vulnerability to stressors and poor health outcomes, such as fractures,
hospitalization and death (Fried et al. 2001; Bortz 2002; Lipsitz 2002; Hamerman 1999).
The physiologic and clinical findings that characterize frailty are not likely to be due to
changes in a single system but to the interaction of several systems resulting in a global
decline (Ford et al. 2003). Sensitivity to nutritional and physiological challenges increases
with age, as do serum Cu levels (Malavolta et al. 2010; Mezzetti et al. 1998). Serum Cu, Zn
and Cu/Zn ratios have been explored as biomarkers (Malavolta et al. 2010) and may well be
markers of frailty. We searched for a relationship between Cu, Zn and Cu/Zn ratio and
physical and mental measures of well-being in a population of frail elderly men to test the
hypothesis that low and/or high Cu levels or abnormal Cu/Zn ratios were associated with
poor physiologic performance and could contribute to the frailty syndrome.
2. Methods
2. 1 Study Population
Frail men aged 60 years or older residing in the community or assisted living were recruited
to participate in the study. The individuals were screened for potential participation in a
previously reported study to assess testosterone effects on bone and frailty in men (Kenny et
al. 2010). The data used in this analysis are baseline assessments. Exclusion criteria: [1]
Diseases or medications known to affect bone or muscle metabolism (i.e. Paget’s disease,
osteomalacia, hyperparathyroidism: current use of corticosteroids, calcitonin, heparin,
phenytoin, phenobarbital, methotrexane, bisphosphonates, selective estrogen receptor
modulator or PTH); [2] Use of estrogen, DHEA or androgen in the preceding year; [3]
Metastatic or advanced cancer (other than skin cancer); [4] History of prostate cancer; [5]
Active cardiac ischemia by history of angina or myocardial infarction in the preceding 6
months; [6] Elevation of PSA; [7] History of sleep apnea; [8] Polycythemia. All study
participants provided written informed consent. The Institutional Review Board at the
University of Connecticut Health Center approved the study.
2.2 Independent Variables
Demographic characteristics collected included age, BMI, and dietary intake by 3 day food
record. Dietary records were analyzed using Food Processor (version8.1; Salem, OR). Bone
assessment included BMD via dual energy absorptiometry (BMD; Lunar DPX-L, Madison,
WI; coefficient of variation of BMD measurement at the proximal femur was <1%), bone
turnover markers (bone formation [BAP, PINP and OC]; markers of bone resorption [NTX
of type I collagen and free DPD], calcium regulating hormone levels [25OHD and PTH],
Gaier et al. Page 2
Exp Gerontol. Author manuscript; available in PMC 2014 February 19.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
and sex hormones (testosterone, estradiol and DHEA) (Kenny et al. 2010). Body
composition ([LBM (kg)], total fat mass (kg)) were obtained (Lunar DPX-L, Madison, WI).
ASM was determined by combining the lean tissue mass of the arms and legs, excluding all
other regions from analysis (Wang et al. 1996). We adjusted ASM for height by dividing
each by height2 (m2). Physical function assessment including frailty evaluation was done as
described (Fried et al. 2001): frail = 3-5 characteristics; intermediate frail =1-2
characteristics; non-frail = 0 characteristics. Leg extension strength [1 repetition maximum
(Judge et al. 1996); intra- and inter-tester variability <10%] and power were measured on the
Keiser Sitting Leg Press. Handgrip strength was measured by Jamar dynamometer. Physical
performance was assessed by the SPPB [ability to rise from a chair, static balance and 8 foot
walk ] (Guralnik et al. 1994), and by the Get-Up-and-Go test (Podsiadlo et al. 1991). Other
health measures included Katz ADLs and IADLs (6), cholesterol panel (6), hematocrit (6)
and medical history.
2.3 Measurement of serum Cu and Zn levels
Inductively coupled plasma mass spectrometry analysis was performed using an Agilent
7700x equipped with an ASX 250 autosampler at a radio frequency power 1550 W, argon
plasma gas flow rate 15 L/min, and Ar carrier gas flow rate of 1.04 L/min. Cu, Fe and Zn
were measured in kinetic energy discrimination mode using He gas (4.3 mL/min). For
analysis, serum samples were diluted 25-fold into 1% HNO3 (Fisher Scientific). Data were
quantified using a 5-point (0-1000 ppb (ng/g)) calibration curve with external standards. For
each sample, data were acquired in triplicate and averaged. An internal standard (Er)
introduced with the sample was used to monitor for plasma instabilities. Cp activity was
measured using o-dianisidine HCl as the substrate (Prohaska 1991). For analysis, subjects
were divided into quintiles based on serum Cu and the Cu/Zn ratio, with comparisons made
between the lowest or highest quintile and the reference (middle quintile). Quintile ranges
were as follows: Serum Cu Low (<836.7 ppb), Reference (906.4-1013.9 ppb), High
(>1193.1 ppb); Cu/Zn Ratio Low (<0.93), Reference (1.12-1.27), High (>1.51).
2.4 Statistical Analysis
Baseline and clinical characteristics were reported using percentages, means and standard
deviations. All variables were checked for normal distribution and the impact of outliers.
Outliers beyond 3 standard deviations were dropped from the analyses (n=3). Correlation
coefficients were used to detect preliminary associations of serum Cu with other measures of
interest. Quintiles for serum metals and the Cu/Zn ratio were defined proportionately and
separate independent t-tests were used to compare the means of the extreme quintiles to the
reference quintile. Statistical analyses were performed using SPSS version 18.0 (Chicago,
IL).
3. Results
3.1 Cu, Zn and the Cu/Zn Ratio
Baseline information and nutritional data for the study population appear in Table 1.
Subjects consumed a mean of 1.21 ± 1.07 mg of Cu and 12.9 ± 10.6 mg of Zn per day.
Serum levels of Cu, Zn and the Cu/Zn ratios were normally distributed among subjects; the
Cu/Zn ratio data are shown in Fig.1. Dietary intake of Cu and Zn shared no statistical
relationship with serum values (not shown). As expected, Cp activity correlated tightly with
serum Cu (not shown). Indicators of bone health, fitness and overall health were compared
to Cu, Zn and Cu/Zn ratios; comparisons to the Cu/Zn ratio proved to be the most
informative.
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3.2 Cu/Zn Ratio and Bone Parameters
Mean BMD and factors contributing to BMD were compared across serum Cu/Zn ratios
(Table 2). The mean femoral neck BMD t-score was −2.12 ± 0.75 g/cm2. Bone turnover
markers, sex hormone levels (data not shown), 25OHD and PTH were typical of levels
found in older men (Kenny et al. 2010). Deficits in BMD were found in individuals in the
high Cu/Zn ratio group (Table 2 and Fig.2A). Femoral neck BMD was also lower in subjects
in the high Cu quintile (0.747 ± 0.113 g/cm2 compared to 0.806 ± 0.070 g/cm2; p=0.031 [not
shown]). No significant associations were found with bone sex hormones or turnover
markers (not shown). PTH was significantly elevated in the high Cu/Zn ratio group (Table 2
and Fig.2B), though no association was found with 25OHD levels.
3.3 Cu/Zn Ratio and Physical Parameters
Most men in the study group (91%) met the criteria for frailty (18%) or prefrailty (72%).
Approximately 50% had ASM/Ht2 values that met criteria for sarcopenia or low muscle
mass associated with aging (Baumgartner et al. 1998). Multiple physical measures,
including whole body lean mass, lean mass corrected for height, handgrip strength, lower
extremity strength and power, and the SPPB, a composite score of lower extremity function,
were impaired in those in the highest quartile of Cu/Zn (Table 3 and Fig.3). Subjects in the
high serum Cu quintile displayed slower best walk speeds (0.76 + 0.26 vs. 0.94 + 0.24 m/
sec; p=0.015) and longer Get-Up-and-Go times (15.6 + 7.2 vs. 11.2 + 3.4 sec; p=0.008 [not
shown]). These relationships did not reach statistical relationships for the Cu/Zn ratio (Table
3).
3.4 Cu/Zn Ratio and Overall Health
Overall, the men in the study group were community dwelling but had some limitation in
function, with 20% requiring assistance in IADLs and 12% requiring ADL assistance. High
Cu/Zn ratio subjects had an increased need for ADL assistance (Table 4). High Cu/Zn ratio
subjects had significantly lower total cholesterol and triglyceride levels (Table 4 and Fig.
4A). Hematocrit values were significantly lower in both the high serum Cu (38.5 + 4.2 vs.
41.5 + 4.2 %; p=0.030 [not shown]) and Cu/Zn ratio (Table 4 and Fig.4B) groups. There
was a significant reduction in serum Fe for subjects in the high Cu/Zn ratio group, but not
for subjects in the high serum Cu group (values). Subjects in these high metal groups did not
have daily dietary Fe intakes different from their respective references (not shown). No
significant differences in hematocrit were found for the low Cu (43.5 + 3.2 vs. 41.5 + 5.0%;
p= 0.08) or low Cu/Zn ratio groups (Table 4).
4. Discussion
In the present study we found significant relationships between high Cu/Zn ratios with lower
BMD, lean mass, strength and power, lower extremity function, cholesterol, hematocrit, and
ADLs. The measures represent clinically relevant indicators of health and independence in a
cohort of frail elderly men. Several recent studies demonstrated a clear link between
increased serum Cu levels and/or Cu/Zn ratios with several progressive, degenerative
diseases (Arnal et al. 2010; Viktorinova et al. 2009) and increased risk for all-cause
mortality in the elderly (Leone et al. 2006; Malavolta et al. 2010). Consistent with previous
reports, we found more consistent and robust associations with serum Cu/Zn ratios than with
Cu levels alone. Our results support use of the Cu/Zn ratio as a functional and predictive
biomarker for overall health, independence and frailty (Malavolta et al. 2010).
The importance of Cu in bone health has been studied in the context of Cu deficiency and
osteoporosis (Palacios 2006; Chaudhri et al. 2009; Lowe et al. 2002). Chaudhri et al.
(Chaudhri et al. 2009) found a linear relationship between serum Cu values and bone density
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in post-menopausal women. By contrast, the men in our study with low serum Cu levels had
BMD similar to those of the reference group. Those with high serum Cu and a high Cu/Zn
ratio had lower BMDs, possibly due to elevated PTH and low 25OHD. These conflicting
results may reflect sex differences in age-associated bone loss or may be due to our
evaluation of an older, more frail population. Nielsen et al. recently found that
supplementing postmenopausal women with Cu and Zn resulted in loss of BMD in those
consuming adequate dietary Zn, while Zn supplementation to reach 8 mg/d prevented BMD
loss. Serum Cu and Zn levels were not reported, precluding comparison to our Cu/Zn ratios.
Nevertheless, these results support our findings indicating that high Cu is negatively
associated with BMD.
There is a complex interplay of Cu and Zn with Mg (Nielsen et al. 2011; Nielsen et al.
2003). While Mg intake in our study group was below the RDA [320 mg/d; (Food and
Nutrition Board and Institute of Medicine 1997)], serum Mg levels were not assessed. Mg
deficiency is associated with decreased osteoblast function and increased osteoclast numbers
(Rude et al. 2009), increased all-cause mortality (Leone et al. 2006) and increased
inflammatory markers (Chacko et al. 2010; Chang et al. 2012). Future studies aimed at
assessing interplay between Cu, Zn and Mg should be informative.
The serum Cu/Zn ratio has been studied in the context of several chronic progressive
diseases. High ratios predicted mortality in cardiovascular and cancer patients in several
prospective studies with 3.5 to 18 year follow-ups (Leone et al. 2006; Malavolta et al. 2010;
Reunanen et al. 1996). Our measures of serum Cu and Zn by mass spectrometry were
consistent with previous values using similar methods (Easter et al. 2010; Malavolta et al.
2010). We found similarly impaired physical function in those in the highest Cu/Zn ratio
group. Older men in the high serum Cu group demonstrated deficits in walking speed and
Get-Up-and-Go test, tasks with a strong cardiovascular component. In contrast, men in the
high serum Cu/Zn ratio group displayed more impaired muscle strength and mass. This
curious divergence likely speaks to distinct interactions between the roles of Cu and Zn in
the cardiovascular and musculoskeletal systems. In a cross-sectional study, Mezzeti et al.
(Mezzetti et al. 1998) found an association between high serum Cu and LDL and
triglycerides that purportedly contributed to the association with cardiovascular disease. We
found that a high Cu/Zn ratio predicted lower triglyceride and total cholesterol levels. These
conflicting results may reflect a survivor effect in the frail elderly and/or differences in
participant selection criteria between studies.
A well-documented symptom of chronic Cu deficiency is anemia that is refractory to Fe
supplementation (Uauy et al. 1998; Halfdanarson et al. 2008) to which the elderly are
susceptible (Carmel 2008). In contrast, we observed a reduction in hematocrit in the high
Cu/Zn ratio group which was accompanied by a reduction in serum Fe levels. This
unexpected result likely reflects the complex interconnected pathways that govern Fe and
Cu homeostasis (Uriu-Adams et al. 2005; Uauy et al. 1998; Collins et al. 2010; Kim et al.
2010). Subclinical anemia could also contribute to a heightened risk of cardiovascular
mortality through long-term increased demand on the heart. Additionally, poor physical
performance of elderly men with high serum Cu and Cu/Zn ratios could arise through
inadequate delivery of oxygen to muscle. Independent of the cause, poor physical
performance by men with high Cu/Zn ratios has major clinical and functional relevance.
Strength, speed and stability contribute to an individual’s level of independence through his
ability to care for himself. Indeed, we found a significantly increased proportion of the men
in the high Cu/Zn group required ADL assistance.
The oxidative properties of Cu and the antioxidant properties of Zn are hypothesized to be
influential factors in chronic progressive conditions such as cardiovascular disease (Leone et
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al. 2006; Reunanen et al. 1996), neurodegenerative disease (Mezzetti et al. 1998; Arnal et al.
2010), and secondary complications of diabetes mellitus (Viktorinova et al. 2009). Many
studies consistently report an age-dependent increase in serum Cu, but a concomitant
reduction in serum Zn predicts disease in an age-independent manner (Malavolta et al. 2010;
Mezzetti et al. 1998). Imbalance of Cu and Zn is thought to result in oxidation of lipids,
which in turn compromises the integrity of vascular and neuronal membranes. In
combination with other factors, oxidative stress mediated through trace metal imbalances
could contribute to the increase in susceptibility to and progression of degenerative diseases
with age.
In conclusion, we characterized a set of significant relationships between serum Cu and Zn
and clinically relevant measures of bone, physical function and independence in frail elderly
men. Our findings highlight the importance and potential clinical utility of trace elements as
serological markers in identifying at-risk elderly and raise a major question for future study:
Can manipulation of Cu and the Cu/Zn ratio alone improve bone health, physical
performance and/or independence? Prospective studies will be needed to test these questions
and to determine the predictive power of serum Cu and Cu/Zn ratios in long-term health.
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Abbreviations
25OHD 25-Hydroxy-vitamin D
ADL Activities of Daily Living
ASM Appendicular Skeletal Mass
BAP Bone-specific Alkaline Phosphatase
BMI Body Mass Index
BMD Bone Mineral Density
Cp Ceruloplasmin
Cu Copper
DHEA Dehydroepiandrosterone
DPD Deoxypyridinoline
HDL High Density Lipoprotein
IADLs Instrumental Activities of Daily Living
LBM Lean Body Mass
LDL Low Density Lipoprotein
NTX Crosslinked N-Telopeptide
OC Osteocalcin
PINP N-terminal type I Procollagen Peptide
PSA Prostate Specific Antigen
PTH Parathyroid Hormone
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SPPB Short Physical Performance Battery
Zn Zinc
Reference List
Arnal N, Cristalli DO, de Alaniz MJ, Marra CA. Clinical utility of copper, ceruloplasmin, and
metallothionein plasma determinations in human neurodegenerative patients and their first-degree
relatives. Brain Res. 2010; 1319:118–130. [PubMed: 20026314]
Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, et al.
Epidemiology of sarcopenia among the elderly in New Mexico. Am.J.Epidemiol. 1998; 147:755–
763. [PubMed: 9554417]
Bortz WM. A conceptual framework of frailty: a review. J.Gerontol.A Biol.Sci.Med.Sci. 2002;
57:M283–M288. [PubMed: 11983721]
Carmel R. Nutritional anemias and the elderly. Semin.Hematol. 2008; 45:225–234. [PubMed:
18809092]
Chacko SA, Song Y, Nathan L, Tinker L, de B, I, Tylavsky F, et al. Relations of dietary magnesium
intake to biomarkers of inflammation and endothelial dysfunction in an ethnically diverse cohort of
postmenopausal women. Diabetes Care. 2010; 33:304–310. [PubMed: 19903755]
Chang SS, Weiss CO, Xue QL, Fried LP. Association between inflammatory-related disease burden
and frailty: results from the Women's Health and Aging Studies (WHAS) I and II.
Arch.Gerontol.Geriatr. 2012; 54:9–15. [PubMed: 21763008]
Chaudhri MA, Kemmler W, Harsch I, Watling RJ. Plasma copper and bone mineral density in
osteopenia: an indicator of bone mineral density in osteopenic females. Biol.Trace Elem.Res. 2009;
129:94–98. [PubMed: 19139831]
Collins JF, Prohaska JR, Knutson MD. Metabolic crossroads of iron and copper. Nutr.Rev. 2010;
68:133–147. [PubMed: 20384844]
Easter RN, Qilin C, Lai B, Ritman EL, Caruso JA, Zhenyu Q. Vascular metallomics: copper in the
vasculature. Vasc.Med. 2010; 15:61–69. [PubMed: 19808712]
Food and Nutrition Board and Institute of Medicine. Dietary Reference Intakes for Calcium,
Phosphorus, Magnesium, Vitamin D, and Fluoride. 1997
Ford ES, Mokdad AH. Dietary magnesium intake in a national sample of US adults. J.Nutr. 2003;
133:2879–2882. [PubMed: 12949381]
Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults:
evidence for a phenotype. J.Gerontol.A Biol.Sci.Med.Sci. 2001; 56:M146–M156. [PubMed:
11253156]
Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, et al. A short physical
performance battery assessing lower extremity function: association with self-reported disability
and prediction of mortality and nursing home admission. J.Gerontol. 1994; 49:M85–M94.
[PubMed: 8126356]
Halfdanarson TR, Kumar N, Li CY, Phyliky RL, Hogan WJ. Hematological manifestations of copper
deficiency: a retrospective review. Eur.J.Haematol. 2008; 80:523–531. [PubMed: 18284630]
Hamerman D. Toward an understanding of frailty. Ann.Intern.Med. 1999; 130:945–950. [PubMed:
10375351]
Judge JO, Schechtman K, Cress E. The relationship between physical performance measures and
independence in instrumental activities of daily living. The FICSIT Group. Frailty and Injury:
Cooperative Studies of Intervention Trials. J.Am.Geriatr.Soc. 1996; 44:1332–1341. [PubMed:
8909349]
Kenny AM, Kleppinger A, Annis K, Rathier M, Browner B, Judge JO, et al. Effects of transdermal
testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone
mass, and physical frailty. J.Am.Geriatr.Soc. 2010; 58:1134–1143. [PubMed: 20722847]
Gaier et al. Page 7
Exp Gerontol. Author manuscript; available in PMC 2014 February 19.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Kim BE, Turski ML, Nose Y, Casad M, Rockman HA, Thiele DJ. Cardiac copper deficiency activates
a systemic signaling mechanism that communicates with the copper acquisition and storage
organs. Cell Metab. 2010; 11:353–363. [PubMed: 20444417]
Leone N, Courbon D, Ducimetiere P, Zureik M. Zinc, copper, and magnesium and risks for all-cause,
cancer, and cardiovascular mortality. Epidemiology. 2006; 17:308–314. [PubMed: 16570028]
Lipsitz LA. Dynamics of stability: the physiologic basis of functional health and frailty. J.Gerontol.A
Biol.Sci.Med.Sci. 2002; 57:B115–B125. [PubMed: 11867648]
Lowe NM, Lowe NM, Fraser WD, Jackson MJ. Is there a potential therapeutic value of copper and
zinc for osteoporosis? Proc.Nutr.Soc. 2002; 61:181–185. [PubMed: 12133199]
Malavolta M, Giacconi R, Piacenza F, Santarelli L, Cipriano C, Costarelli L, et al. Plasma copper/zinc
ratio: an inflammatory/nutritional biomarker as predictor of all-cause mortality in elderly
population. Biogerontology. 2010; 11:309–319. [PubMed: 19821050]
Mezzetti A, Pierdomenico SD, Costantini F, Romano F, De CD, Cuccurullo F, et al. Copper/zinc ratio
and systemic oxidant load: effect of aging and aging-related degenerative diseases. Free
Radic.Biol.Med. 1998; 25:676–681. [PubMed: 9801067]
Nielsen FH, Lukaski HC, Johnson LK, Roughead ZK. Reported zinc, but not copper, intakes influence
whole-body bone density, mineral content and T score responses to zinc and copper
supplementation in healthy postmenopausal women. Br.J.Nutr. 2011; 106:1872–1879. [PubMed:
21733304]
Nielsen FH, Milne DB. Some magnesium status indicators and oxidative metabolism responses to low-
dietary magnesium are affected by dietary copper in postmenopausal women. Nutrition. 2003;
19:617–626. [PubMed: 12831948]
Palacios C. The role of nutrients in bone health, from A to Z. Crit Rev.Food Sci.Nutr. 2006; 46:621–
628. [PubMed: 17092827]
Podsiadlo D, Richardson S. The timed "Up & Go": a test of basic functional mobility for frail elderly
persons. J.Am.Geriatr.Soc. 1991; 39:142–148. [PubMed: 1991946]
Prohaska JR. Changes in Cu,Zn-superoxide dismutase, cytochrome c oxidase, glutathione peroxidase
and glutathione transferase activities in copper-deficient mice and rats. J.Nutr. 1991; 121:355–363.
[PubMed: 1848285]
Reunanen A, Knekt P, Marniemi J, Maki J, Maatela J, Aromaa A. Serum calcium, magnesium, copper
and zinc and risk of cardiovascular death. Eur.J.Clin.Nutr. 1996; 50:431–437. [PubMed: 8862478]
Rude RK, Singer FR, Gruber HE. Skeletal and hormonal effects of magnesium deficiency.
J.Am.Coll.Nutr. 2009; 28:131–141. [PubMed: 19828898]
Uauy R, Olivares M, Gonzalez M. Essentiality of copper in humans. Am.J.Clin.Nutr. 1998; 67:952S–
959S. [PubMed: 9587135]
Uriu-Adams JY, Keen CL. Copper, oxidative stress, and human health. Mol.Aspects Med. 2005;
26:268–298. [PubMed: 16112185]
Viktorinova A, Toserova E, Krizko M, Durackova Z. Altered metabolism of copper, zinc, and
magnesium is associated with increased levels of glycated hemoglobin in patients with diabetes
mellitus. Metabolism. 2009; 58:1477–1482. [PubMed: 19592053]
Wang ZM, Visser M, Ma R, Baumgartner RN, Kotler D, Gallagher D, et al. Skeletal muscle mass:
evaluation of neutron activation and dual-energy X-ray absorptiometry methods. J.Appl.Physiol.
1996; 80:824–831. [PubMed: 8964743]
Gaier et al. Page 8
Exp Gerontol. Author manuscript; available in PMC 2014 February 19.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig. 1. Serum Metals
Graph depicts frequency histogram for the Cu/Zn ratio. Values for serum Cu and serum Zn
were also normally distributed. Vertical lines denote quintile boundaries.
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Fig. 2. Bone Mineral Density (BMD) and Parathyroid Hormone (PTH)
(A) BMD was assessed from the femoral neck of each subject. (B) Subjects in the high Cu/
Zn ratio group had significantly higher PTH values than their reference group cohorts.
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Fig. 3. Muscle Strength and Short Physical Performance Battery (SPPB)
(A) Subjects were tested for muscle strength by measuring power generated by right leg
press. Individuals in the high Cu/Zn ratio generated significantly less power than the
reference group. (B) Individuals in the high Cu/Zn ratio group achieved significantly lower
SPPB scores than individuals in the reference group.
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Fig. 4. Lipid Metabolism and Hematocrit
(A) Individuals in the high Cu/Zn group had significantly lower triglyceride levels than the
reference group. (B) Individuals in the high Cu/Zn ratio groups had significantly lower
hematocrit values than subjects in their respective reference groups.
Gaier et al. Page 12
Exp Gerontol. Author manuscript; available in PMC 2014 February 19.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Gaier et al. Page 13
Table 1
Study Population Characteristics
Mean ± SD
(N=144)
Age (yrs) 77.1 ± 7.6
BMI (kg/m2) 26.9 ± 4.4
% (N)
Heart disease 30 (38)
Hypertension 23 (30)
On Ciioiesteroi Medication 28 (36)
On Hypertension Medication 41 (59)
Nutrition
(per day) Mean ± SD
Calories 2046 ± 1130
Calcium (mg) 898 ± 660
Vitamin D (IU) 209 ± 276
Copper (mg) 1.21 ± 1.07
Protein (g) 94.8 ± 51.5
Magnesium (mg) 285.4 ± 161.9
Zinc (mg) 12.9 ± 10.6
Iron (mg) 19.8 ± 12.9
Serum Levels
Mean ± SD
Copper (ppb) 1009 ± 241
Ceruloplasmin (μU/μL) 188.4 ± 46.3
Zinc (ppb) 877 ± 281
Iron (ppb) 970 ± 531
Copper/Zinc Ratio 1.22 ± 0.37
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Table 2
Cu/Zn ratio groupings by bone mineral density and Ca regulating hormones
Group
average
(n=79)
Low
(n=26)
Reference
(n=27)
High
(n=26)
P
values
Low
P
values
High
Femoral Neck BMD
(g/cm2)
0.794 ±
0.098
0.802 ±
0.063
0.823 ±
0.116
0.750 ±
0.090
0.416 0.014
Femoral Total BMD
(g/cm2)
0.886 ±
0.113
0.907 ±
0.078
0.921 ±
0.124
0.833 ±
0.122
0.631 0.012
Femoral Trochanter BMD
(g/cm2)
0.794 ±
0.121
0.801 ±
0.089
0.837 ±
0.135
0.743 ±
0.133
0.253 0.013
Vitamin D (nmol/L) 86.5 ± 36.2 83.9 ±
35.1
78.8 ± 24.6 78.1 ± 37.0 0.545 0.930
iPTH (pg/mL) 69.7 ± 47.9 57.1 ±
21.0
61.1 ± 23.0 89.0 ± 55.4 0.519 0.020
Bold represents p values <0 .05.
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Table 3
Cu/Zn ratio groupings by frailty and physical performance
Group
average
(n=74)
Low
(n=24)
Reference
(n=27)
High
(n=23)
P
values
Low
P
values
High
Nonfrail % (n) 9 (12) 7 (2) 15 (4) 4 (1) 0.413 0.172
Prefrail % (n) 72 (94) 85 (22) 70 (19) 65 (17) 0.215 0.697
Frail % (n) 18 (24) 8 (2) 15 (4) 31 (8) 0.413 0.165
ASM (Kg) 22.5 ± 3.5 22.8 ± 3.6 23.6 ± 2.9 21.0 ± 3.1 0.406 0.003
ASM/Ht2 7.6 ± 1.0 7.7 ± 1.0 7.9 ± 1.0 7.3 ± 0.9 0.590 0.042
Whole body lean mass
(Kg)
53 ± 7 53.8 ± 7.7 55.5 ± 5.1 50.0 ± 5.8 0.350 0.001
Leg Press Strength
(Newtons)
666 ± 207 713 ± 228 697 ± 190 564 ± 202 0.779 0.021
Leg Press Power (Watts) 254 ± 135 309 ± 163 296 ± 137 195 ± 94 0.754 0.005
Handgrip (Kg) 25.3 ± 8.2 24.2 ± 8.1 29.5 ± 8.7 23.0 ± 8.0 0.029 0.009
Walk best speed (m/sec) 0.89 ± 0.23 0.95 ± 0.16 0.95 ± 0.25 0.81 ± 0.26 0.994 0.064
Get-Up-and-Go (secs) 12.8 ± 8.0 10.6 ± 2.0 11.4 ± 4.4 14.6 ± 7.0 0.433 0.056
SPPB score 9.0 ± 2.6 10.4 ± 1.3 9.7 ± 2.2 7.8 ± 3.0 0.178 0.014
Bold represents p values <0.05.
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Table 4
Cu/Zn ratio groupings by overall health
Group
average
(n=74)
Low
(n=24)
Reference
(n=27)
High
(n=23)
P
values
Low
P
values
High
IADL needs assistance %
(n)
20 (24) 4 (1) 11 (3) 32 (7) 0.357 0.074
ADL needs assistance %
(n)
12 (15) 4 (2) 0 22 (5) 0.284 0.011
Total cholesterol (mg/dL) 188 ± 38 184 ± 40 193 ± 29 173 ± 40 0.333 0.041
Triglycerides (mg/dL) 119 ± 75 131 ± 115 138 ± 64 84 ± 49 0.785 0.001
HCT (%) 41.6 ± 4.3 43.0 ± 2.9 43.0 ± 3.8 39.0 ± 5.1 0.990 0.002
Bold represents p values < 0.05.
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